Last reviewed · How we verify

NCT06567002

A Study of MK-6552 and the Effect of Food in Healthy Participants (MK-6552-006)

Terminated Phase 1 Last updated 4 December 2024
What this trial tests

Phase 1 trial testing MK-6552 in Healthy in 24 participants. Terminated before completion.

Timeline
9 September 2024
Primary endpoint
15 November 2024
15 November 2024

Quick facts

Lead sponsorMerck Sharp & Dohme LLC
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposebasic science
Enrollment24
Start date9 September 2024
Primary completion15 November 2024
Estimated completion15 November 2024
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to learn what happens to levels of MK-6552 in the blood when MK-6552 is given in different forms to healthy adult participants under fasted and fed conditions.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MK-6552

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06567002.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing